BV Insider Notice: 70,000 Shares Planned Sale on NYSE
Rhea-AI Filing Summary
BrightView Holdings, Inc. (BV) submitted a Form 144 notice to sell 70,000 shares of its common stock, with an aggregate market value of $1,034,305.70. The filing lists the number of outstanding shares as 94,900,000 and identifies the proposed sale date as 08/25/2025 on the NYSE.
The securities to be sold were acquired between 11/14/2019 and 12/01/2024 through employee stock purchase plan purchases and restricted stock vesting, with payment characterized as cash for ESPP purchases and compensation for vested awards. The notice states there were no securities sold by the reporting person in the past three months and includes the procedural representation required by the form.
Positive
- Full disclosure of planned sale: filing specifies 70,000 shares, aggregate value $1,034,305.70, proposed date 08/25/2025, and NYSE as the exchange
- Clear provenance: acquisition history from 11/14/2019 to 12/01/2024 shows ESPP purchases and restricted stock vesting with payment types listed
Negative
- None.
Insights
TL;DR: Routine insider sale notice for 70,000 shares; disclosure provides timing, value, and acquisition history.
The filing is a standard Form 144 indicating an intended sale rather than a completed transaction. It discloses the proposed sale size (70,000 shares) and aggregate market value ($1,034,305.70) and specifies the exchange and approximate sale date. Acquisition records span 2019–2024 and show the shares originated from ESPP purchases and restricted stock vesting, indicating these are likely employee-held shares. For investors, this is procedural disclosure without evidence within the form of material operational or financial developments.
TL;DR: The filing documents compliance with Rule 144 and provides required provenance of the shares to be sold.
The notice properly lists the broker, proposed sale date, exchange, outstanding share count, and a detailed acquisition timeline for the securities to be sold. The acquisition entries identify ESPP purchases and restricted stock vesting with payment characterized as cash or compensation, satisfying provenance disclosure. The signer also attests there is no undisclosed material adverse information, consistent with the form's certification requirements. The document does not, by itself, indicate any governance events or irregularities.